Get the Stockscreener App
150.51
0.46%
-0.69
Pre-market:
132.01
-18.50
-12.29%
Neurocrine Biosciences Inc Stock (NBIX) Latest News
abrdn plc Purchases 20,150 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Reports Strong Growth in 2024 - TipRanks
Neurocrine Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - Marketscreener.com
Jennison Associates LLC Purchases 485,894 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Robeco Institutional Asset Management B.V. Sells 372,648 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug - MSN
Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates - Yahoo Finance
Neurocrine: Q4 Earnings Snapshot -February 06, 2025 at 04:28 pm EST - Marketscreener.com
Neurocrine Biosciences CEO sells $235,577 in stock - MSN
Neurocrine: Q4 Earnings Snapshot - The Bakersfield Californian
Earnings Summary: Neurocrine Biosciences Q4 - Benzinga
Earnings Flash (NBIX) Neurocrine Biosciences, Posts Q4 Revenue $627.7M, vs. FactSet Est of $629.5M - Marketscreener.com
Major Win for Neurocrine: Record INGREZZA Sales Hit $615M as New Drug Gets FDA Green Light - StockTitan
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Swedbank AB - MarketBeat
Chicago Partners Investment Group LLC Acquires New Stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Sells $413,954.44 in Stock - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CFO Matt Abernethy Sells 1,283 Shares - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) CEO Sells $235,572.67 in Stock - MarketBeat
Insider Selling: Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Insider Sells 1,740 Shares of Stock - MarketBeat
Neurocrine Biosciences executive sells shares worth $266,024 - MSN
Neurocrine Biosciences officer sells $168,849 in stock - MSN
Neurocrine Biosciences chief legal officer sells $191,133 in stock - MSN
Neurocrine Biosciences CCO sells shares worth $184,598 - MSN
STATE STREET CORP Reduces Stake in Neurocrine Biosciences Inc - GuruFocus.com
Neurocrine Biosciences chief scientific officer sells $19,273 in stock - MSN
Neurocrine Biosciences CCO sells shares worth $184,598 By Investing.com - Investing.com South Africa
Is Neurocrine Biosciences, Inc.'s (NASDAQ:NBIX) Recent Stock Performance Tethered To Its Strong Fundamentals? - Simply Wall St
Neurocrine Biosciences chief medical officer sells $222,636 in stock - MSN
China Universal Asset Management Co. Ltd. Acquires 2,047 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences CEO sells $235,577 in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences chief legal officer sells $191,133 in stock By Investing.com - Investing.com Australia
Neurocrine Biosciences director Kevin Gorman sells $413,966 in stock - MSN
Neurocrine Biosciences officer sells $168,849 in stock By Investing.com - Investing.com Canada
Neurocrine Biosciences executive sells shares worth $266,024 By Investing.com - Investing.com South Africa
Neurocrine Biosciences CFO sells shares worth $196,135 By Investing.com - Investing.com Nigeria
Neurocrine Biosciences chief medical officer sells $222,636 in stock By Investing.com - Investing.com UK
Neurocrine Biosciences CFO sells shares worth $196,135 - Investing.com
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings) - Benzinga
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges - MSN
Neurocrine Biosciences, Inc. (NBIX): Among the Best Low Risk High Growth Stocks To Invest In Now - Insider Monkey
Neurocrine (NBIX) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures - Yahoo Finance
Morgan Stanley Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval - Seeking Alpha
Mediolanum International Funds Ltd Sells 3,558 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Research Analysts Offer Predictions for NBIX Q1 Earnings - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $176.00 - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Kevin Charles Gorman Sells 146,105 Shares - MarketBeat
Synergy Asset Management LLC Purchases New Position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Leerink Partnrs Has Bearish Outlook for NBIX FY2024 Earnings - MarketBeat
0.07%
0.46%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):